Nivolumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.

**Synonyms:** - ABP 206 - BCD-263 - BMS 936558 - BMS-936558 - BMS936558 - CMAB819 - MDX 1106 - MDX-1106 - MDX1106 - NIVO - NIVOLUMAB - Nivolumab Biosimilar ABP 206 - Nivolumab Biosimilar BCD-263 - Nivolumab Biosimilar CMAB819 - ONO 4538 - ONO-4538 - ONO4538 - Opdivo